E. Lévy

502 total citations
32 papers, 279 citations indexed

About

E. Lévy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Dermatology. According to data from OpenAlex, E. Lévy has authored 32 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Dermatology. Recurrent topics in E. Lévy's work include Cancer Treatment and Pharmacology (7 papers), Immunotherapy and Immune Responses (4 papers) and Chemotherapy-related skin toxicity (4 papers). E. Lévy is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Immunotherapy and Immune Responses (4 papers) and Chemotherapy-related skin toxicity (4 papers). E. Lévy collaborates with scholars based in France, United States and Cameroon. E. Lévy's co-authors include Karen Leroy, M C Voisin, J. Revuz, Alain Créange, Laurent Lantieri, Nadine Martin‐Garcia, J Zeller, Janine Wechsler, Joseph Gligorov and Israel Lowy and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and British Journal of Cancer.

In The Last Decade

E. Lévy

31 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Lévy France 8 124 71 69 55 47 32 279
Masao Edagawa Japan 10 91 0.7× 152 2.1× 84 1.2× 67 1.2× 41 0.9× 24 352
Khoon Leong Chuah Singapore 9 118 1.0× 108 1.5× 41 0.6× 90 1.6× 25 0.5× 30 349
Florence Burtin France 8 116 0.9× 75 1.1× 42 0.6× 20 0.4× 97 2.1× 17 307
Jean-François Emile France 5 130 1.0× 150 2.1× 34 0.5× 82 1.5× 111 2.4× 11 361
Paul Chih‐Hsueh Chen Taiwan 9 140 1.1× 91 1.3× 136 2.0× 93 1.7× 16 0.3× 9 379
Maria Rosaria Limiti Italy 9 94 0.8× 102 1.4× 18 0.3× 68 1.2× 29 0.6× 15 364
Michifumi Kohno Japan 10 64 0.5× 87 1.2× 26 0.4× 27 0.5× 49 1.0× 30 275
Kouichi Isobe Japan 13 127 1.0× 105 1.5× 116 1.7× 71 1.3× 28 0.6× 30 430
Libin Xu China 13 82 0.7× 106 1.5× 45 0.7× 147 2.7× 98 2.1× 41 507
Luisa Santoro Italy 10 123 1.0× 89 1.3× 17 0.2× 94 1.7× 37 0.8× 32 347

Countries citing papers authored by E. Lévy

Since Specialization
Citations

This map shows the geographic impact of E. Lévy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Lévy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Lévy more than expected).

Fields of papers citing papers by E. Lévy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Lévy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Lévy. The network helps show where E. Lévy may publish in the future.

Co-authorship network of co-authors of E. Lévy

This figure shows the co-authorship network connecting the top 25 collaborators of E. Lévy. A scholar is included among the top collaborators of E. Lévy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Lévy. E. Lévy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schoeffler, A., E. Lévy, J.‐L. Schmutz, et al.. (2013). Syndrome de Stevens-Johnson et maladie de Hodgkin : association fortuite ou syndrome paranéoplasique ?. Annales de Dermatologie et de Vénéréologie. 141(2). 134–140. 2 indexed citations
2.
Lévy, E., Bénédicte Neven, Natacha Entz‐Werlé, B. Cribier, & Dan Lipsker. (2012). Vitiligo post-greffe thymique chez un enfant porteur d’un déficit en Foxn1. Annales de Dermatologie et de Vénéréologie. 139(6-7). 468–471. 5 indexed citations
3.
Curtit, Elsa, Nadine Dohollou, E. Lévy, et al.. (2011). Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. European Journal of Cancer. 47(16). 2396–2402. 9 indexed citations
4.
Fajac, Anne, Joseph Gligorov, Keyvan Rezaï, et al.. (2010). Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. British Journal of Cancer. 103(4). 560–566. 28 indexed citations
5.
Ray‐Coquard, Isabelle, B. Weber, J Crétin, et al.. (2009). Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. British Journal of Cancer. 100(4). 601–607. 20 indexed citations
6.
Mays, Theresa A., John Sarantopoulos, Anthony W. Tolcher, et al.. (2006). MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer. Journal of Clinical Oncology. 24(18_suppl). 14549–14549. 3 indexed citations
7.
Oudard, Stéphane, Eugéniu Banu, F. Scotté, et al.. (2005). Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. Journal of Clinical Oncology. 23(16_suppl). 4634–4634. 8 indexed citations
8.
Mennecier, B., et al.. (2004). MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC): Interim phase II data. Journal of Clinical Oncology. 22(14_suppl). 2544–2544. 3 indexed citations
9.
Scotté, Florian, J.M. Tourani, Eugéniu Banu, et al.. (2004). Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. Journal of Clinical Oncology. 22(14_suppl). 8003–8003. 4 indexed citations
10.
Bouillet, T., Pierre Saintigny, E. Lévy, et al.. (2004). Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study. Journal of Clinical Oncology. 22(14_suppl). 783–783. 5 indexed citations
11.
Braud, A.C., E. Lévy, F Feuilhade, et al.. (2002). Combination of Vinorelbine, Epirubicin, and Cyclophosphamide as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. American Journal of Clinical Oncology. 25(3). 303–307. 5 indexed citations
12.
Rieux, Claire, et al.. (2000). Radiation-induced bone sarcoma following total body irradiation: role of additional radiation on localized areas. Bone Marrow Transplantation. 25(9). 1011–1013. 10 indexed citations
13.
Lipton, Allan, James R. Berenson, R. Knight, Grace Hu, & E. Lévy. (1999). Phase 2 trial of Zoledronate vs Pamidronate in multiple myeloma and breast cancer. European Journal of Cancer. 35. S360–S360. 3 indexed citations
14.
Méllière, D, et al.. (1999). Cancers anaplasiques de la thyroïde. La guérison est-elle possible ?. Chirurgie. 124(1). 52–57. 11 indexed citations
15.
Lévy, E., P. Thirion, & Pascal Piedbois. (1997). Chimiothérapie adjuvante des sarcomes des tissus mous. Cancer/Radiothérapie. 1(5). 462–466. 1 indexed citations
16.
Shani, Adi, Aliza K. Fink, E. Lévy, et al.. (1986). Antitumor immune response to colorectal cancer antigen detected by the leukocyte adherence inhibition test (LAI) in groups at high risk for colorectal cancer.. PubMed. 9(5-6). 485–90. 1 indexed citations
17.
Frileux, P, et al.. (1985). [Postoperative peritonitis of colonic origin. Apropos of 155 cases].. PubMed. 39(9). 649–59. 7 indexed citations
18.
Lévy, E., et al.. (1985). [Postoperative peritonitis of supramesocolic origin. 114 cases].. PubMed. 39(9). 621–9. 3 indexed citations
19.
Cosnes, J., et al.. (1980). [Continuous enteral feeding to reduce diarrhea and steatorrhea following ileal resection (author's transl)].. PubMed. 4(10). 695–9. 6 indexed citations
20.
Lévy, E., et al.. (1980). [The severe acute colitis syndrome. Prognosis evaluation. A report of one hundred cases (author's transl)].. PubMed. 3(8-9). 637–45. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masao Edagawa Breakdown of academic impact, for papers by Khoon Leong Chuah Breakdown of academic impact, for papers by Florence Burtin Breakdown of academic impact, for papers by Jean-François Emile Breakdown of academic impact, for papers by Paul Chih‐Hsueh Chen Breakdown of academic impact, for papers by Maria Rosaria Limiti Breakdown of academic impact, for papers by Michifumi Kohno Breakdown of academic impact, for papers by Kouichi Isobe Breakdown of academic impact, for papers by Libin Xu Breakdown of academic impact, for papers by Luisa Santoro
Rankless by CCL
2026